Compare Angi Inc (ANGI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs BIO-TECHNE Corp — how do they compare? Angi Inc trades at $4.5 (market cap $186.15M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 60.4× Angi Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Angi Inc pays none. Which is the better fit depends on your goals.
| ANGI | TECH | |
|---|---|---|
Market Cap | $186.15M | $11.24B |
Sector | Media | Health |
52-Week High | $18.46 | $72.29 |
52-Week Low | $4.59 | $43.31 |
Enterprise Value | $395.93M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.84, down 2.42% on the day, with a bearish technical signal and mixed earnings history. Revenue has declined from $1.9B in 2022 to $1.03B in 2025, though net income turned positive in 2024-2025 before a projected loss in 2026. The stock trades at low valuation multiples (P/E 14.81, P/S 0.21), but faces challenges with negative ROE and ROA. Recent news highlights Q2 2026 earnings misses and ongoing investigations into the company.
The outlook is cautious due to declining revenue, accelerating pro user churn, and negative cash flow projections. Analyst consensus is a $7.00 price target with a 'Hold' bias, but risks include platform deterioration, legal scrutiny, and lack of clear catalysts. Upside depends on stabilizing the core marketplace and executing a viable AI strategy.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
